Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Not only can you, the research suggests you may want to
Study 4 was a 68-week trial that enrolled 611 patients with obesity (BMI greater than or equal to 30 kg/m2) or with overweight (BMI 27 to 29.9 kg/m2) and at least one weight-related comorbid condition such as treated or untreated dyslipidemia or hypertension
It seems that weight loss will likely be very important for the benefits of the GLP-1 medicines in some conditions, and much less important, or not at all essential, for benefits in other disorders. According to Lane, although GLP-1 receptor agonists show promise in reducing cardiovascular risk factors, long-term cardiovascular safety trials are needed to assess cardiovascular mortality and events
These effects are proportional to weight loss speed and amount, making them slightly more common with tirzepatide due to greater average weight loss
Sorimachi, H
